Investors are experiencing a volatile stock market, with the Nasdaq 100 index showing both greater gains and significant losses compared to the S&P 500 and Dow Jones.
Dexcom has suffered a 31% decline recently due to lowered guidance for earnings, highlighting challenges from competition, particularly from Abbott Labs in the CGM market.
[
Collection
]
[
|
...
]